Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report published on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Performance

Akari Therapeutics stock opened at $1.36 on Thursday. The company’s 50-day moving average price is $1.69 and its 200-day moving average price is $2.52. Akari Therapeutics has a twelve month low of $1.08 and a twelve month high of $5.50.

Institutional Investors Weigh In On Akari Therapeutics

A hedge fund recently raised its stake in Akari Therapeutics stock. Omnia Family Wealth LLC boosted its position in shares of Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,628 shares of the biopharmaceutical company’s stock after buying an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned 1.55% of Akari Therapeutics worth $273,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.